• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从 COVID-19 重症患者中分离出的多重耐药革兰氏阴性菌的临床特征和危险因素。

Clinical characteristics and risk factors for the isolation of multi-drug-resistant Gram-negative bacteria from critically ill patients with COVID-19.

机构信息

Division of Critical Care, Department of Medicine, Hamad Medical Corporation, Doha, Qatar.

Division of Critical Care, Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.

出版信息

J Hosp Infect. 2021 Apr;110:165-171. doi: 10.1016/j.jhin.2021.01.027. Epub 2021 Feb 6.

DOI:10.1016/j.jhin.2021.01.027
PMID:33561503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7866848/
Abstract

BACKGROUND

We investigated the clinical characteristics and risk factors for the isolation of multi-drug-resistant (MDR) Gram-negative bacteria (GNB) from critically ill COVID-19 patients.

METHODS

We retrospectively matched (1:2) critical COVID-19 patients with one or more MDR GNB from any clinical specimen (cases), with those with no MDR GNB isolates (controls).

RESULTS

Seventy-eight cases were identified (4.5 per 1000 intensive care unit (ICU) days, 95% confidence interval (CI) 3.6-5.7). Of 98 MDR GNB isolates, the most frequent species were Stenotrophomonas maltophilia (24, 24.5%), and Klebsiella pneumoniae (23, 23.5%). Two (8.7%) K. pneumoniae, and six (85.7%) Pseudomonas aeruginosa isolates were carbapenem resistant. A total of 24 (24.5%) isolates were not considered to be associated with active infection. Those with active infection received appropriate antimicrobial agents within a median of one day. The case group had significantly longer median central venous line days, mechanical ventilation days, and hospital length of stay (P<0.001 for each). All-cause mortality at 28 days was not significantly different between the two groups (P=0.19). Mechanical ventilation days (adjusted odds ratio 1.062, 95% CI 1.012-1.114; P=0.015), but not receipt of corticosteroids or tocilizumab, was independently associated with the isolation of MDR GNB. There was no association between MDR GNB and 28-day all-cause mortality (adjusted odds ratio 2.426, 95% CI 0.833-7.069; P= 0.104).

CONCLUSION

In critically ill COVID-19 patients, prevention of MDR GNB colonization and infections requires minimizing the use of invasive devices, and to remove them as soon as their presence is no longer necessary.

摘要

背景

我们研究了从危重症 COVID-19 患者中分离出多重耐药(MDR)革兰氏阴性菌(GNB)的临床特征和危险因素。

方法

我们回顾性地将任何临床标本中分离出一种或多种 MDR GNB 的危重症 COVID-19 患者(病例)与未分离出 MDR GNB 株的患者(对照组)进行 1:2 匹配。

结果

共确定了 78 例病例(每 1000 个 ICU 天 4.5 例,95%置信区间 3.6-5.7)。在 98 株 MDR GNB 分离株中,最常见的菌种为嗜麦芽寡养单胞菌(24 株,24.5%)和肺炎克雷伯菌(23 株,23.5%)。2 株(8.7%)肺炎克雷伯菌和 6 株(85.7%)铜绿假单胞菌分离株对碳青霉烯类药物耐药。共有 24 株(24.5%)分离株被认为与活动性感染无关。在接受适当的抗菌药物治疗后,有活动性感染的患者在中位数为 1 天内接受了治疗。病例组的中位中心静脉导管天数、机械通气天数和住院时间明显更长(P<0.001)。两组 28 天全因死亡率无显著差异(P=0.19)。机械通气天数(调整优势比 1.062,95%置信区间 1.012-1.114;P=0.015),而非皮质类固醇或托珠单抗的使用与 MDR GNB 的分离有关。MDR GNB 与 28 天全因死亡率无关联(调整优势比 2.426,95%置信区间 0.833-7.069;P=0.104)。

结论

在危重症 COVID-19 患者中,预防 MDR GNB 定植和感染需要尽量减少使用侵入性设备,并在其不再需要时尽快去除。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c84/7866848/a07b1db14352/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c84/7866848/a07b1db14352/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c84/7866848/a07b1db14352/gr1_lrg.jpg

相似文献

1
Clinical characteristics and risk factors for the isolation of multi-drug-resistant Gram-negative bacteria from critically ill patients with COVID-19.从 COVID-19 重症患者中分离出的多重耐药革兰氏阴性菌的临床特征和危险因素。
J Hosp Infect. 2021 Apr;110:165-171. doi: 10.1016/j.jhin.2021.01.027. Epub 2021 Feb 6.
2
The rising influx of multidrug-resistant gram-negative bacilli into a tertiary care hospital.多重耐药革兰氏阴性杆菌大量涌入一家三级护理医院。
Clin Infect Dis. 2005 Jun 15;40(12):1792-8. doi: 10.1086/430314. Epub 2005 May 6.
3
The Increasing Challenge of Multidrug-Resistant Gram-Negative Bacilli: Results of a 5-Year Active Surveillance Program in a Neonatal Intensive Care Unit.多重耐药革兰氏阴性杆菌带来的挑战日益增加:新生儿重症监护病房一项为期5年的主动监测项目结果
Medicine (Baltimore). 2016 Mar;95(10):e3016. doi: 10.1097/MD.0000000000003016.
4
Multidrug-resistant gram-negative bacteria in patients with COVID-19: An epidemiological and clinical study.COVID-19 患者中的多药耐药革兰氏阴性菌:一项流行病学和临床研究。
J Infect Public Health. 2023 Aug;16(8):1184-1192. doi: 10.1016/j.jiph.2023.05.017. Epub 2023 May 17.
5
The health facility as a risk factor for multidrug-resistant gram-negative bacteria in critically ill patients with COVID-19.医疗机构成为 COVID-19 重症患者耐多药革兰氏阴性菌的危险因素。
Clinics (Sao Paulo). 2022 Oct 17;77:100130. doi: 10.1016/j.clinsp.2022.100130. eCollection 2022.
6
Risk factors and mortality associated with multi-drug-resistant Gram-negative bacterial infection in adult patients following abdominal surgery.腹部手术后成年患者多重耐药革兰氏阴性菌感染的危险因素及死亡率
J Hosp Infect. 2022 Jan;119:22-32. doi: 10.1016/j.jhin.2021.09.021. Epub 2021 Oct 7.
7
Bacterial profile, and independent predictors for healthcare-associated pneumonia persistently caused by multidrug-resistant Gram-negative bacteria for patients with the preceding multidrug-resistant Gram-negative pneumonia in Taiwan.台湾地区先前患有多重耐药革兰氏阴性菌肺炎患者,持续性多重耐药革兰氏阴性菌所致医源性肺炎的细菌谱及独立预测因子。
J Microbiol Immunol Infect. 2024 Oct;57(5):801-811. doi: 10.1016/j.jmii.2024.07.009. Epub 2024 Aug 6.
8
High Prevalence of Antimicrobial Resistance Among Gram-Negative Isolated Bacilli in Intensive Care Units at a Tertiary-Care Hospital in Yucatán Mexico.墨西哥尤卡坦州一家三级医院重症监护病房中革兰氏阴性杆菌的抗生素耐药率很高。
Medicina (Kaunas). 2019 Sep 13;55(9):588. doi: 10.3390/medicina55090588.
9
Efficacy of a coordinated strategy for containment of multidrug-resistant Gram-negative bacteria carriage in a Neonatal Intensive Care Unit in the context of an active surveillance program.主动监测方案背景下,新生儿重症监护病房中针对多重耐药革兰氏阴性菌携带采取协调防控策略的效果。
Antimicrob Resist Infect Control. 2021 Feb 4;10(1):30. doi: 10.1186/s13756-021-00902-1.
10
Infection with multidrug-resistant gram-negative bacteria in a pediatric oncology intensive care unit: risk factors and outcomes.儿科肿瘤重症监护病房中多重耐药革兰氏阴性菌感染:危险因素与结局
J Pediatr (Rio J). 2015 Sep-Oct;91(5):435-41. doi: 10.1016/j.jped.2014.11.009. Epub 2015 Jun 6.

引用本文的文献

1
Prevalence and genetic characterization of clinically relevant extended-spectrum β-lactamase-producing in the Gulf Cooperation Council countries.海湾合作委员会国家中临床相关产超广谱β-内酰胺酶菌株的流行情况及基因特征分析
Front Antibiot. 2023 Jun 26;2:1177954. doi: 10.3389/frabi.2023.1177954. eCollection 2023.
2
Bacterial infections and outcomes of inpatients with COVID-19 in the intensive care unit during the delta-dominant phase: the worst wave of pandemic in Iran.德尔塔变异株主导阶段 ICU 住院 COVID-19 患者的细菌感染和结局:伊朗疫情最严重的一波。
Front Public Health. 2024 Sep 9;12:1411314. doi: 10.3389/fpubh.2024.1411314. eCollection 2024.
3

本文引用的文献

1
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.托珠单抗治疗 COVID-19 患者的疗效和安全性:一项实时系统评价和荟萃分析。
Clin Microbiol Infect. 2021 Feb;27(2):215-227. doi: 10.1016/j.cmi.2020.10.036. Epub 2020 Nov 5.
2
Do Contact Precautions Reduce the Incidence of Intensive Care Unit-Acquired Pseudomonas aeruginosa Infections? The DPCPYO (Detection and Contact Precautions for Patients With P. aeruginosa) Cluster-Randomized Crossover Trial.实施接触预防措施能否降低 ICU 获得性铜绿假单胞菌感染的发生率?DPCPYO(铜绿假单胞菌感染患者的检测和接触预防措施)整群随机交叉试验。
Clin Infect Dis. 2021 Nov 2;73(9):e2781-e2788. doi: 10.1093/cid/ciaa1663.
3
Incidence of Carbapenem-Resistant Gram-Negative Bacterial Infections in Critically Ill Patients with COVID-19 as Compared to Non-COVID-19 Patients: A Prospective Case-Control Study.
与非COVID-19患者相比,COVID-19重症患者中耐碳青霉烯类革兰氏阴性菌感染的发生率:一项前瞻性病例对照研究。
Crit Care Res Pract. 2024 Jun 22;2024:7102082. doi: 10.1155/2024/7102082. eCollection 2024.
4
Antimicrobial Resistance in Qatar: Prevalence and Trends before and Amidst the COVID-19 Pandemic.卡塔尔的抗菌药物耐药性:新冠疫情之前及期间的流行情况和趋势
Antibiotics (Basel). 2024 Feb 21;13(3):203. doi: 10.3390/antibiotics13030203.
5
An Emergent Change in Epidemiologic and Microbiological Characteristics of Bloodstream Infections in Adults With Febrile Neutropenia Resulting From Chemotherapy for Acute Leukemia and Lymphoma at Reference Centers in Chile, Ecuador, and Peru.智利、厄瓜多尔和秘鲁参考中心接受化疗的急性白血病和淋巴瘤成人发热性中性粒细胞减少症患者血流感染的流行病学和微生物学特征的紧急变化。
Open Forum Infect Dis. 2024 Feb 1;11(3):ofae052. doi: 10.1093/ofid/ofae052. eCollection 2024 Mar.
6
Comparative De Novo and Pan-Genome Analysis of MDR Nosocomial Bacteria Isolated from Hospitals in Jeddah, Saudi Arabia.沙特阿拉伯吉达市医院分离出的多重耐药医院感染细菌的比较从头测序和泛基因组分析
Microorganisms. 2023 Sep 28;11(10):2432. doi: 10.3390/microorganisms11102432.
7
A Systematic Review of Antimicrobial Resistance During the COVID-19 Pandemic.COVID-19 大流行期间的抗菌药物耐药性系统评价
Hawaii J Health Soc Welf. 2023 Aug;82(8):188-193.
8
Multidrug-Resistant Bacterial Colonization and Infections in Large Retrospective Cohort of Mechanically Ventilated COVID-19 Patients.机械通气 COVID-19 患者的大型回顾性队列中的多重耐药菌定植和感染。
Emerg Infect Dis. 2023 Aug;29(8):1598-1607. doi: 10.3201/eid2908.230115.
9
An rRNA fragment in extracellular vesicles secreted by human airway epithelial cells increases the fluoroquinolone sensitivity of .人呼吸道上皮细胞分泌的细胞外囊泡中的 rRNA 片段增加了 流感嗜血杆菌对氟喹诺酮类药物的敏感性
Am J Physiol Lung Cell Mol Physiol. 2023 Jul 1;325(1):L54-L65. doi: 10.1152/ajplung.00150.2022. Epub 2023 May 31.
10
Burden of severe infections due to carbapenem-resistant pathogens in intensive care unit.重症监护病房中耐碳青霉烯类病原体所致严重感染的负担
World J Clin Cases. 2023 May 6;11(13):2874-2889. doi: 10.12998/wjcc.v11.i13.2874.
Tocilizumab in patients with severe COVID-19: a retrospective cohort study.
托珠单抗治疗重症新型冠状病毒肺炎患者:一项回顾性队列研究
Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24.
4
Symptoms of burnout in intensive care unit specialists facing the COVID-19 outbreak.重症监护病房专家在面对新冠疫情时的职业倦怠症状。
Ann Intensive Care. 2020 Aug 8;10(1):110. doi: 10.1186/s13613-020-00722-3.
5
Antibiotic use in patients with COVID-19: a 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey.COVID-19 患者中的抗生素使用情况:传染病国际研究倡议 (ID-IRI) 的“快照”调查。
J Antimicrob Chemother. 2020 Nov 1;75(11):3386-3390. doi: 10.1093/jac/dkaa326.
6
Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.COVID-19 患者的细菌合并感染和继发感染:一项实时快速综述和荟萃分析。
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629. doi: 10.1016/j.cmi.2020.07.016. Epub 2020 Jul 22.
7
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
8
Infection prevention and control in nursing severe coronavirus disease (COVID-19) patients during the pandemic.大流行期间护理重症冠状病毒病(COVID-19)患者时的感染预防与控制
Crit Care. 2020 Jun 12;24(1):338. doi: 10.1186/s13054-020-03076-1.
9
Co-infections in people with COVID-19: a systematic review and meta-analysis.COVID-19 患者合并感染:系统评价和荟萃分析。
J Infect. 2020 Aug;81(2):266-275. doi: 10.1016/j.jinf.2020.05.046. Epub 2020 May 27.
10
COVID-19 pandemic-a focused review for clinicians.COVID-19 大流行——临床医生重点关注。
Clin Microbiol Infect. 2020 Jul;26(7):842-847. doi: 10.1016/j.cmi.2020.04.023. Epub 2020 Apr 25.